BeadArray™-based solutions for enabling the promise of pharmacogenomics

被引:20
作者
Fan, JB
Hu, SX
Craumer, WC
Barker, DL
机构
[1] Illumina Inc, San Diego, CA 92121 USA
[2] IMS Management Consulting, Plymouth Meeting, PA USA
关键词
D O I
10.2144/000112047
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A "one-size-fits-all" approach continues to characterize today's healthcare paradigm. But emergent rules, information, genomics tools, and economics are driving a fundamental and inevitable shift to a more personalized world of medicine. In this new world, the interests of insurers, regulators, suppliers, healthcare providers, and most important, patients, will have converged. The new goal will be the right treatment for the right individual at the right time. In this world, personalized medicine, through pharmacogenomics (PGx), will be the new healthcare paradigm. We will briefly examine healthcare trends and current opportunities for PGx development. We will then demonstrate how microarray technologies-among them bead-based approaches-have emerged as a key enabler for bringing home the promise of PGx.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 56 条
[31]   Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction [J].
Lehmann, U ;
Glöckner, S ;
Kleeberger, W ;
Feist, H ;
von Wasielewski, R ;
Kreipe, H .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (06) :1855-1864
[32]   Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective [J].
Lesko, LJ ;
Woodcock, J .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (09) :763-769
[33]  
Lewis F, 2001, J PATHOL, V195, P66, DOI 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO
[34]  
2-F
[35]   ROLE FOR DNA METHYLATION IN GENOMIC IMPRINTING [J].
LI, E ;
BEARD, C ;
JAENISCH, R .
NATURE, 1993, 366 (6453) :362-365
[36]   Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes [J].
Lossos, IS ;
Czerwinski, DK ;
Alizadeh, AA ;
Wechser, MA ;
Tibshirani, R ;
Botstein, D ;
Levy, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1828-1837
[37]   Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer [J].
Martens, JWM ;
Nimmrich, I ;
Koenig, T ;
Look, MP ;
Harbeck, N ;
Model, F ;
Kluth, A ;
Bolt-De Vries, J ;
Sieuwerts, AM ;
Portengen, H ;
Gelder, MEM ;
Piepenbrock, C ;
Olek, A ;
Höfler, H ;
Kiechle, M ;
Klijn, JGM ;
Schmitt, M ;
Maier, S ;
Foekens, JA .
CANCER RESEARCH, 2005, 65 (10) :4101-4107
[38]   Prognostic DNA methylation marker in serum of cancer patients [J].
Müller, HM ;
Fiegl, H ;
Widschwendter, A ;
Widschwendter, M .
CIRCULATING NUCLEIC ACIDS IN PLASMA/SERUM III AND SERUM PROTEOMICS, 2004, 1022 :44-49
[39]  
OLIPHANT A, 2002, BIOTECHNIQUES S, V56, P61
[40]   A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J].
Paik, S ;
Shak, S ;
Tang, G ;
Kim, C ;
Baker, J ;
Cronin, M ;
Baehner, FL ;
Walker, MG ;
Watson, D ;
Park, T ;
Hiller, W ;
Fisher, ER ;
Wickerham, DL ;
Bryant, J ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2817-2826